HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takanori Ueda Selected Research

Philadelphia Chromosome

6/2011[Nilotinib as a second-line treatment for chronic myeloid leukemia].
1/2007INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
9/2003The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
1/2003Expression of the antiapoptotic gene survivin in chronic myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takanori Ueda Research Topics

Disease

34Leukemia
08/2015 - 05/2002
19Neoplasms (Cancer)
01/2021 - 03/2002
17Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2018 - 01/2003
12Hyperuricemia
10/2016 - 04/2008
11Hematologic Neoplasms (Hematological Malignancy)
10/2022 - 11/2006
10Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
09/2014 - 05/2002
8Heart Failure
06/2008 - 02/2003
7Lymphoma (Lymphomas)
01/2021 - 01/2006
7Gout
01/2015 - 04/2008
7BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
02/2014 - 08/2002
6Myocardial Infarction
08/2013 - 05/2002
6Coronary Artery Disease (Coronary Atherosclerosis)
03/2007 - 11/2003
5Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2021 - 11/2012
5Multiple Myeloma
12/2017 - 11/2008
5Tumor Lysis Syndrome
12/2016 - 10/2014
5Hematologic Diseases (Blood Diseases)
04/2013 - 02/2003
5Infarction (Infarctions)
06/2012 - 05/2002
4Neutropenia
10/2022 - 03/2002
4Communicable Diseases (Infectious Diseases)
06/2014 - 03/2004
4Disease Progression
06/2014 - 09/2012
4Myelodysplastic Syndromes (Myelodysplastic Syndrome)
09/2012 - 01/2003
4Sepsis (Septicemia)
05/2012 - 01/2002
4Philadelphia Chromosome
06/2011 - 01/2003
3Acute Promyelocytic Leukemia
11/2018 - 02/2003
3Pathologic Constriction (Stenosis)
10/2016 - 12/2013
3Myeloid Leukemia (Leukemia, Myelocytic)
10/2014 - 05/2013
3Bacteremia
04/2013 - 01/2002
3Drug-Related Side Effects and Adverse Reactions
06/2011 - 06/2011
3Atherosclerosis
07/2009 - 10/2004
2Mycoses (Diseases, Fungus)
10/2022 - 01/2004
2Febrile Neutropenia
10/2022 - 03/2004
2Disseminated Intravascular Coagulation
11/2018 - 01/2011
2Nausea
01/2018 - 11/2017
2Vomiting
01/2018 - 11/2017
2Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
09/2015 - 01/2014
2Lesch-Nyhan Syndrome (Choreoathetosis Self Mutilation Hyperuricemia Syndrome)
01/2015 - 01/2014
2Scrub Typhus (Typhus, Scrub)
06/2014 - 04/2010
2Residual Neoplasm
10/2013 - 03/2008
2Cytokine Release Syndrome
02/2013 - 10/2006

Drug/Important Bio-Agent (IBA)

14Uric Acid (Urate)IBA
10/2016 - 04/2008
13Cytarabine (Cytosar-U)FDA LinkGeneric
04/2014 - 02/2003
9FebuxostatFDA Link
10/2016 - 06/2011
8Pharmaceutical PreparationsIBA
01/2021 - 11/2006
8Xanthine OxidaseIBA
10/2016 - 06/2011
8DNA (Deoxyribonucleic Acid)IBA
10/2013 - 11/2002
7SurvivinIBA
12/2017 - 01/2003
7Proteins (Proteins, Gene)FDA Link
11/2008 - 11/2002
6Allopurinol (Remid)FDA LinkGeneric
10/2016 - 06/2011
6CytokinesIBA
01/2015 - 01/2002
6purineIBA
12/2014 - 06/2011
6Matrix Metalloproteinases (MMPs)IBA
01/2012 - 12/2002
5Prednisolone (Predate)FDA LinkGeneric
09/2017 - 06/2002
5Rituximab (Mabthera)FDA Link
09/2017 - 08/2005
5Doxorubicin (Adriamycin)FDA LinkGeneric
02/2015 - 05/2003
5Imatinib Mesylate (Gleevec)FDA Link
06/2008 - 08/2002
5MagnesiumIBA
01/2006 - 02/2003
5Caspase 3 (Caspase-3)IBA
01/2006 - 05/2002
4Vincristine (Oncovin)FDA LinkGeneric
01/2021 - 05/2003
4Dexamethasone (Maxidex)FDA LinkGeneric
09/2015 - 05/2002
4Carmustine (FIVB)FDA Link
08/2015 - 11/2002
4Melphalan (Alkeran)FDA LinkGeneric
08/2015 - 06/2004
49-arabinofuranosylguanineIBA
09/2014 - 02/2010
4Anti-Bacterial Agents (Antibiotics)IBA
06/2014 - 01/2002
4Folic Acid (Vitamin M)FDA LinkGeneric
01/2006 - 11/2003
3Phenobarbital (Luminal)FDA Link
10/2016 - 12/2013
3Mitoxantrone (Novantrone)FDA LinkGeneric
09/2015 - 03/2005
3Biological ProductsIBA
01/2015 - 07/2007
3Messenger RNA (mRNA)IBA
08/2013 - 01/2003
3Inhibitor of Apoptosis ProteinsIBA
05/2013 - 01/2003
3Cyclosporine (Ciclosporin)FDA LinkGeneric
09/2012 - 06/2002
3Member 1 Subfamily B ATP Binding Cassette TransporterIBA
09/2012 - 03/2005
3fludarabineIBA
10/2011 - 06/2005
3triphosphoric acid (triphosphate)IBA
09/2011 - 11/2006
3Glutathione (Reduced Glutathione)IBA
03/2010 - 05/2002
2ElectrolytesIBA
10/2022 - 02/2005
2ThrombomodulinIBA
11/2018 - 01/2011
2Dacarbazine (DIC)FDA LinkGeneric
11/2018 - 01/2011
2sepantroniumIBA
12/2017 - 05/2013
2Bortezomib (Velcade)FDA Link
12/2017 - 12/2016
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/2017 - 02/2015
2rasburicase (Elitek)FDA Link
10/2016 - 05/2015
2Temozolomide (Temodar)FDA LinkGeneric
08/2015 - 07/2008
2Acetylcysteine (Siran)FDA LinkGeneric
03/2015 - 07/2009
2Nitric Oxide (Nitrogen Monoxide)FDA Link
03/2015 - 03/2012
2Hypoxanthine Phosphoribosyltransferase (Hypoxanthine Guanine Phosphoribosyltransferase)IBA
01/2015 - 01/2014
2Interleukin-2 Receptors (IL 2 Receptor)IBA
01/2015 - 11/2012
2nelarabine (506U78)FDA Link
09/2014 - 02/2010
2Phosphotransferases (Kinase)IBA
07/2014 - 06/2008
2ChemokinesIBA
06/2014 - 09/2008
2Clofarabine (Clolar)FDA Link
04/2014 - 09/2011
2Antineoplastic Agents (Antineoplastics)IBA
03/2014 - 04/2013
2Dasatinib (BMS 354825)FDA Link
02/2014 - 06/2011
2Glucose (Dextrose)FDA LinkGeneric
08/2013 - 08/2006
2Oxygen (Dioxygen)IBA
08/2013 - 02/2007
2Arabinofuranosylcytosine TriphosphateIBA
04/2013 - 06/2009

Therapy/Procedure

23Drug Therapy (Chemotherapy)
10/2022 - 03/2002
23Therapeutics
10/2022 - 03/2002
3Remission Induction
01/2011 - 06/2002
2Molecular Targeted Therapy
02/2014 - 10/2007
2Stem Cell Transplantation
10/2013 - 06/2004